Table. 3 Survival data
Parameter | Mean survival (months) | Median survival (months) | P-Value | ||||||
|---|---|---|---|---|---|---|---|---|---|
CI 95% | CI 95% | ||||||||
Estimate | SE | Lower limit | Higher limit | Estimate | SE | Lower limit | Higher limit | ||
Sex | |||||||||
Males | 16.2 | 3.1 | 10.2 | 22.1 | 8 | 3 | 2.1 | 13.9 | 0.04* |
Females | 8.8 | 2.1 | 2.7 | 10.8 | 3 | 1.8 | 0 | 6.6 | |
Age | |||||||||
< 63 yrs | 11.4 | 3.3 | 5 | 17.8 | 5 | 1.5 | 2.1 | 7.9 | 0.58 |
≥ 63 yrs | 16.1 | 3.5 | 9.2 | 22.9 | 12 | 2.7 | 6.7 | 17.3 | |
Histotype | |||||||||
Epithelioid | 17.4 | 3.2 | 11.2 | 23.6 | 10 | 2.2 | 5.7 | 14.3 | |
Biphasic | 7 | 3 | 1.2 | 12.8 | 2 | 0.6 | 0.9 | 3.1 | 0.002* |
Sarcomatoid | 2.8 | 1 | 0.7 | 4.8 | 1 | ||||
Tumor grading | |||||||||
Low | 25.3 | 5.5 | 14.5 | 36 | 14 | 3.7 | 6.7 | 21.3 | 0.004* |
High | 10 | 3 | 4.1 | 15.9 | 5 | 0.7 | 3.6 | 6.4 | |
Nuclear grading | |||||||||
2 | 27.8 | 5.2 | 17.6 | 37.9 | 18 | 10 | 0 | 37.6 | < 0.0001* |
3 | 8.2 | 2.3 | 3.6 | 12.7 | 5 | 0.7 | 3.6 | 6.4 | |
Ki67 | |||||||||
Low | 24.1 | 4.3 | 15.8 | 32.5 | 14 | 2.7 | 8.8 | 19.2 | |
High | 5.5 | 1.3 | 2.9 | 8.1 | 4 | 0.7 | 2.6 | 5.4 | < 0.0001* |
p16/CDKN2A | |||||||||
No deletion | 22 | 8.8 | 4.7 | 39.3 | 6 | 6.4 | 0 | 18.5 | |
Heterozygous | 23.7 | 5.5 | 12.9 | 34.3 | 12 | 2.7 | 6.8 | 17.3 | 0.002* |
Homozygous | 7 | 1.5 | 4.1 | 10 | 4 | 0.9 | 2.3 | 5.8 | |